PMID- 10569533
OWN - NLM
STAT- MEDLINE
DCOM- 20000106
LR  - 20230302
IS  - 0022-5347 (Print)
IS  - 0022-5347 (Linking)
VI  - 162
IP  - 6
DP  - 1999 Dec
TI  - Chromosome 9 monosomy by fluorescence in situ hybridization of bladder irrigation 
      specimens is predictive of tumor recurrence.
PG  - 1900-3
AB  - PURPOSE: Bladder irrigation specimens are effective for sampling the urothelium 
      for detection of recurrent bladder cancer. These specimens can be evaluated by 
      cytology or quantitative techniques. Proliferation and ploidy changes are readily 
      detected using deoxyribonucleic acid (DNA) cytometry. Tumor associated 
      chromosomal aberrations can be assayed using fluorescence in situ hybridization 
      (FISH). The prognostic values of DNA cytometry, and chromosome 9 and 9p21 FISH on 
      exfoliated cells from bladder irrigation specimens from 61 bladder cancer 
      patients were evaluated. MATERIALS AND METHODS: A total of 61 consecutive bladder 
      irrigation specimens were obtained during cystoscopy. DNA cytometry was performed 
      by image analysis. FISH was performed using a centromeric chromosome 9 probe and 
      a cosmid contig (COSp16) probe to the CDKN2A/p16 tumor suppressor region of 9p21. 
      Proportional hazards regression analysis was performed with statistical software 
      to test the predictor variables of initial patient status (presence of tumor), 
      COSp16 fraction (the proportion of COSp16 signals relative to centromeric probe 
      signals), monosomic and hyperdisomic fractions of the chromosome 9 probe, and 
      hyperdiploid fraction from DNA cytometry. Median time to recurrence was 
      calculated using statistical software survival analysis. RESULTS: Initial patient 
      status and monosomy of chromosome 9 were predictive of bladder cancer recurrence 
      (p <0.0001 and p = 0.0073, respectively). The 11 patients with chromosome 9 
      monosomy fractions greater than 15% and a visible tumor had a median time to 
      recurrence of 105 days. In contrast, only 8 of the 25 patients with chromosome 9 
      monosomy fractions less than 15% and no visible tumor had recurrence within 560 
      days. Median time to recurrence was 185 days for 6 patients with chromosome 9 
      monosomy fractions greater than 15% and no visible tumor, and 225 for 19 with 
      chromosome 9 monosomy fractions less than 15% and a visible tumor. Hyperdiploid 
      fraction was suggestive but not predictive of bladder cancer recurrence (p = 
      0.078). COSp16 and hyperdisomic fractions were not predictive of bladder tumor 
      recurrence (p = 0.11 and p = 0.30, respectively). CONCLUSIONS: Chromosome 9 
      monosomy by FISH was predictive of bladder tumor recurrence. Furthermore, our 
      findings support the hypothesis that losses of tumor suppressor genes on 
      chromosome 9 are critical, perhaps initiating genetic events in bladder cancer.
FAU - Jung, I
AU  - Jung I
AD  - Department of Urology, University of Rochester, New York, USA.
FAU - Reeder, J E
AU  - Reeder JE
FAU - Cox, C
AU  - Cox C
FAU - Siddiqui, J F
AU  - Siddiqui JF
FAU - O'Connell, M J
AU  - O'Connell MJ
FAU - Collins, L
AU  - Collins L
FAU - Yang, Z
AU  - Yang Z
FAU - Messing, E M
AU  - Messing EM
FAU - Wheeless, L L
AU  - Wheeless LL
LA  - eng
GR  - CA33148/CA/NCI NIH HHS/United States
GR  - CA56989/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Urol
JT  - The Journal of urology
JID - 0376374
SB  - IM
CIN - J Urol. 1999 Dec;162(6):1957-8. PMID: 10569546
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chromosomes, Human, Pair 9/*genetics
MH  - Female
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Monosomy/*genetics
MH  - Neoplasm Recurrence, Local/*diagnosis/*genetics
MH  - Predictive Value of Tests
MH  - Therapeutic Irrigation
MH  - Urinary Bladder Neoplasms/*diagnosis/*genetics
EDAT- 1999/11/24 00:00
MHDA- 1999/11/24 00:01
CRDT- 1999/11/24 00:00
PHST- 1999/11/24 00:00 [pubmed]
PHST- 1999/11/24 00:01 [medline]
PHST- 1999/11/24 00:00 [entrez]
AID - S0022-5347(05)68064-0 [pii]
AID - 10.1016/S0022-5347(05)68064-0 [doi]
PST - ppublish
SO  - J Urol. 1999 Dec;162(6):1900-3. doi: 10.1016/S0022-5347(05)68064-0.